Startups
Edit
https://www.bharatserums.com/
Bharat Serums and Vaccines Limited
TrustedLast activity: 17.09.2026
Active
Bharat Serums And Vaccines Limited is one of the fastest leading bio pharmaceutical companies in India.
BSV established in 1971 by the late Dr. Vinod Daftary researches, develops, manufactures, and markets injectable biological, pharmaceutical, and biotechnology products.
BSV's products portfolio includes plasma derivatives, monoclonals, fertility hormones, antifungals, anaesthetics, cardiovascular drugs, and equine immunoglobulin /antitoxins.
The R&D of drug delivery systems, biotechnology/recombinant therapeutics, and biological/equine products; In addition, BSV offers products in the areas of gynaecology, assisted reproductive technology, critical care, emergency medicine, neurology, nephrology, haematology, and urology.
The company provides its products to retail outlets and hospitals through distributors primarily in India, as well as in the Asia Pacific, the Russian Federation, CIS countries, Latin America, Africa, and internationally.
BSV is amongst the top 10 Biotech companies in India. The Company has in its portfolio over 62 brands. The company has over 750 employees selling its products across the country. Our brands are marketed all over India and exported to over 45 countries across the world
We have an open and entrepreneurial culture, with each of our employees taking on significant responsibility in each activity of our value chain, be it in terms of research & development, manufacturing, quality, sales & marketing, distribution, business development or organisation building.
So if you are someone who is looking for a robust learning curve and enjoys taking responsibilities, you have landed on the right company page.
BSV established in 1971 by the late Dr. Vinod Daftary researches, develops, manufactures, and markets injectable biological, pharmaceutical, and biotechnology products.
BSV's products portfolio includes plasma derivatives, monoclonals, fertility hormones, antifungals, anaesthetics, cardiovascular drugs, and equine immunoglobulin /antitoxins.
The R&D of drug delivery systems, biotechnology/recombinant therapeutics, and biological/equine products; In addition, BSV offers products in the areas of gynaecology, assisted reproductive technology, critical care, emergency medicine, neurology, nephrology, haematology, and urology.
The company provides its products to retail outlets and hospitals through distributors primarily in India, as well as in the Asia Pacific, the Russian Federation, CIS countries, Latin America, Africa, and internationally.
BSV is amongst the top 10 Biotech companies in India. The Company has in its portfolio over 62 brands. The company has over 750 employees selling its products across the country. Our brands are marketed all over India and exported to over 45 countries across the world
We have an open and entrepreneurial culture, with each of our employees taking on significant responsibility in each activity of our value chain, be it in terms of research & development, manufacturing, quality, sales & marketing, distribution, business development or organisation building.
So if you are someone who is looking for a robust learning curve and enjoys taking responsibilities, you have landed on the right company page.
Overview
Location
India, Maharashtra, Navi Mumbai
Employees
201-500
Phone
+91 22 4504 3456
Founded date
1971
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 16
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 8, 2026 | Kotak VC fund settles with SEBI over five-year delay in winding up | Credit: VCCircle A venture capital fund that Kotak Mahindra Group’s alternative investment arm raised nearly two decades ago has settled a case with the Securities and and Exchange Board of India for a five-year delay in winding up and dist... |
| Feb 3, 2026 | Advent International to invest $305 mn in Aditya Birla Housing | Shweta Jalan, managing partner and head-India, Advent International Private equity firm Advent International will invest Rs 2,750 crore (about $305 million) in Aditya Birla Housing Finance Ltd, the mortgage lending arm of Aditya Birla Capit... |
| Jun 11, 2025 | Advent makes liquidity move from India portfolio as it joins the PE exit party | Pro Shweta Jalan, managing partner and head-India, Advent International Global private equity firm Advent International has made its first exit move of 2025 from its India portfolio after two big-ticket liquidity moves last year, joining a ... |
| Dec 17, 2024 | PE firm Advent to return a record ₹25,000 cr this year from India portfolio | Private equity firm Advent International will be returning around a record ₹25,000 crore this year to its limited partners (LPs) from gains on its India portfolio, aided by a couple of large ticket, profitable exits, sources said. “That’s a... |
| Oct 21, 2024 | The Empathetic Boss: Rajeev Juneja, MD and VC, Mankind Pharma Rajeev credits the company mantra of 'staying dynamic' as the reason behind its tremendous success over the years | Thirty-three years ago, the idea of Mankind Pharma became a reality with 20 employees and a seed capital of INR 5,000,000. Fast forward to 2024, it has a market capitalization of approximately INR 1.06 trillion and is the fourth-largest pha... |
| Aug 21, 2024 | Advent eyes benchmark returns from second portfolio exit in 2024 | Premium Shweta Jalan, managing partner and head - India, Advent Global private equity firm Advent International, which has been active in India this year having struck an exit from Bharat Serums and making fresh bets in two companies, is no... |
| Aug 19, 2024 | Advent International plans $300-400 m IPO of Manjushree Technopack | Advent International is looking at an initial public offering in the range $300-400 million for its portfolio company Manjushree Technopack with a valuation of $1.5-2 billion, sources said. In 2018, the US-based global private equity firm h... |
| Jul 29, 2024 | Bharat Serums and Vaccines would run as an independent business, says Mankind’s Rajeev Juneja | Days after Mankind Pharma inked a ₹13,630 crore deal to buy Bharat Serums and Vaccines (BSV), its top management said BSV would run as an independent business, reporting to the Mankind board. BSV presented itself as an attractive opportunit... |
| Jul 26, 2024 | Mankind Pharma Acquires Bharat Serums and Vaccines for INR 13,630 Cr The biopharmaceutical company Bharat Serums was set up in 1971, with Vinod Daftary opening a blood bank and eventually launching an injectable for expecting mothers. | Mankind Pharma announced that it has entered into a definitive agreement to acquire a 100 percent stake in Bharat Serums and Vaccines (BSV) from private equity firm Advent International for an enterprise value of INR 13,630 crore. "Thi... |
Show more
Reviews 0
FAQ about Bharat Serums and Vaccines Limited
When was Bharat Serums and Vaccines Limited founded?
Bharat Serums and Vaccines Limited was founded in 1971.
What has the press written about Bharat Serums and Vaccines Limited?
Parsers VC has collected 16 articles mentioning Bharat Serums and Vaccines Limited, among them “Kotak VC fund settles with SEBI over five-year delay in winding up” (Jun 8, 2026) and “Advent International to invest $305 mn in Aditya Birla Housing” (Feb 3, 2026).
Is Bharat Serums and Vaccines Limited still active?
Yes, Bharat Serums and Vaccines Limited is active; its latest activity on Parsers VC dates from Sep 17, 2026.